Free Trial
NASDAQ:CGON

CG Oncology Q4 2024 Earnings Report

CG Oncology logo
$69.62 +0.44 (+0.64%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$69.62 0.00 (0.00%)
As of 05/8/2026 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.37
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A

CG Oncology Revenue Results

Actual Revenue
$0.46 million
Expected Revenue
$0.11 million
Beat/Miss
Beat by +$353.00 thousand
YoY Revenue Growth
N/A

CG Oncology Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, March 28, 2025
Conference Call Time
7:00AM ET

CG Oncology Earnings Headlines

$30 stock to buy before Starlink goes public (WATCH NOW!)
A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.tc pixel
See More CG Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email.

About CG Oncology

CG Oncology (NASDAQ:CGON) (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates. The company’s discovery engine integrates high-throughput screening, structure-based design and biomarker development, enabling rapid iteration and selection of molecules with favorable pharmacological profiles.

Since its founding, CG Oncology has built a management team with extensive experience in oncology drug development, regulatory strategy and commercial planning. The organization continues to expand its pipeline by pursuing additional immuno-oncology targets and exploring strategic collaborations to accelerate the translation of its antibody assets from preclinical research into the clinic. Through these efforts, CG Oncology aims to create differentiated therapies that address unmet needs in the treatment of solid tumor malignancies.

View CG Oncology Profile